PT-CY With or Without Low-dose ATG for Lymphoid Malignancies Undergoing Allo-HSCT
Status:
Completed
Trial end date:
2021-05-01
Target enrollment:
Participant gender:
Summary
All patients received Flu-BU-VP16 as myeloablative conditioning followed by cyclophosphamide
(D+3 and +4) and subsequent tacrolimus. For patients with unrelated or haplo-donor received
low-dose ATG at Day +15.